DRD5

DRD5 is a D1-like G protein-coupled dopamine receptor whose activation translates dopamine signaling into control of inflammation, immunity, autophagy, and tissue homeostasis (PMID:32035036, PMID:34001860). In macrophages, the receptor uses its EFD motif and an IYX(X)I/L motif in its C-terminus and third intracellular loop to recruit TRAF6 together with its negative regulator ARRB2, assembling a complex containing TAK1, IKKs, and PP2A that impairs TRAF6-mediated NF-κB activation; through this ARRB2-PP2A axis dopamine-DRD5 signaling suppresses TLR2-driven pro-inflammatory gene expression and protects against S. aureus sepsis and meningitis (PMID:32035036). DRD5 signaling also shapes macrophage fate, restraining M1 polarization via NF-κB while promoting M2 polarization through CREB, such that receptor deficiency worsens experimental colitis (PMID:34001860). In the tumor context the receptor exerts dual outputs: agonist-driven DRD5 activation raises ROS, inhibits mTOR, and induces autophagic cell death in pituitary and other cancer cells (PMID:28613975), and DRD5 signaling in B cells engages JAK1-STAT1 to enhance antigen presentation and expand cytotoxic CD8+ T cells (PMID:40023842). In the heart, progressive loss of D5R expression accompanies ventricular hypertrophy, and restoring D5R attenuates hypertrophy and fibrosis by limiting oxidative stress, ER stress, and autophagic dysregulation (PMID:33717857). The human gene maps to chromosome 4p15.1-p15.3 (PMID:8288248).

1. 1993 Medium

   Before functional characterization, the genomic position of DRD5 was unknown; mapping it provided the chromosomal anchor and a polymorphic marker for subsequent genetic studies.

   Evidence In situ hybridization and somatic cell hybrid panel with linkage analysis in CEPH pedigrees

   PMID:8288248

   Open questions at the time

   • Establishes location but no protein function
   • No link to any phenotype or signaling pathway
2. 2017 Medium

   It was unclear how DRD5 activation affects tumor cell viability; agonist treatment showed it raises ROS, inhibits mTOR, and triggers autophagic cell death, defining a pro-death signaling output.

   Evidence DRD5 agonist (SKF83959) on pituitary and other cancer cell lines with ROS/mTOR/autophagy assays and gastric cancer xenografts

   PMID:28613975

   Open questions at the time

   • No genetic rescue or receptor-null controls cited
   • G protein coupling and proximal effectors of the mTOR-autophagy axis not defined
3. 2019 Low

   Whether DRD5 could substitute for DRD2 in dopamine-resistant pituitary tumors was untested; a DRD5-specific agonist inhibited growth in tumors with high DRD5 and low DRD2, nominating DRD5 as an alternative target.

   Evidence Immunohistochemistry and MTS viability assays with SKF38393 in primary human pituitary tumor cultures

   PMID:31216815

   Open questions at the time

   • Pharmacological agonist without genetic controls
   • Correlative receptor expression only
   • Mechanism of growth inhibition not delineated
4. 2020 High

   How dopamine signaling restrains inflammation was unresolved; this work mapped specific DRD5 motifs recruiting TRAF6, ARRB2, and PP2A to suppress NF-κB, establishing a receptor-intrinsic anti-inflammatory mechanism with in vivo protection.

   Evidence Reciprocal Co-IP, motif mutagenesis, cell-based signaling assays, and mouse S. aureus sepsis/meningitis models with knockdown/knockout

   PMID:32035036

   Open questions at the time

   • Structural basis of motif-effector recognition not resolved
   • Whether the same complex operates in non-macrophage cell types untested
5. 2021 Medium

   The role of DRD5 in macrophage fate was unknown; knockout studies showed DRD5 inhibits M1 via NF-κB and drives M2 via CREB, linking the receptor to mucosal inflammatory balance.

   Evidence Drd5 knockout mice, experimental colitis, macrophage polarization assays, NF-κB/CREB analysis, D1-like agonist

   PMID:34001860

   Open questions at the time

   • Connection between the CREB arm and the TRAF6-PP2A complex unresolved
   • Single lab, two pathways assessed
6. 2021 Medium

   DRD5's role in cardiac remodeling was unaddressed; gain- and loss-of-function in vivo showed D5R expression protects against hypertrophy by limiting oxidative/ER stress and autophagic dysregulation.

   Evidence TAC mouse model with Drd5 plasmid/siRNA nanoparticle delivery, stress and autophagy markers, human hypertrophic cardiomyopathy validation

   PMID:33717857

   Open questions at the time

   • Downstream effectors linking D5R to ER stress control unclear
   • Causal direction of expression loss versus hypertrophy not fully separated
7. 2021 Medium

   A contrasting pro-tumor role emerged in esophageal cancer, where DRD5 signaling enhanced the Warburg effect via mTOR-AKT crosstalk to promote proliferation, indicating context-dependent metabolic outputs.

   Evidence Proliferation, glucose uptake, lactate, ECAR (Seahorse), mTOR/AKT inhibitor studies, xenografts, patient tumor expression

   PMID:33898321

   Open questions at the time

   • Reconciliation with autophagic cell death output in other cancers unresolved
   • Pathway placement inferred from inhibitor studies
8. 2025 Medium

   Whether DRD5 contributes to antitumor immunity beyond myeloid cells was open; B cell DRD5 signaling was shown to activate JAK1-STAT1 to boost antigen presentation and CD8+ T cell expansion.

   Evidence B cell signaling assays, JAK1-STAT1 analysis, co-culture, in vivo tumor models, dopamine-B cell correlation

   PMID:40023842

   Open questions at the time

   • Direct receptor-to-JAK1 coupling mechanism not defined
   • Single study, single lab

• It remains unresolved how a single receptor produces opposing outputs across tissues, including pro-death autophagy versus Warburg-promoting proliferation and anti- versus pro-inflammatory effects.
• G protein coupling specificity across cell types undefined
• No structural model of effector recruitment
• Determinants of context-dependent mTOR outcome unknown